13058_2018_1091_MOESM1_ESM.pdf (331 kB)
Download file

Additional file 1: of Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)

Download (331 kB)
journal contribution
posted on 31.01.2019, 05:00 by Simon Gampenrieder, Andreas Peer, Christian Weismann, Matthias Meissnitzer, Gabriel Rinnerthaler, Johanna Webhofer, Theresa Westphal, Marina Riedmann, Thomas Meissnitzer, Heike Egger, Frederike Klaassen Federspiel, Roland Reitsamer, Cornelia Hauser-Kronberger, Katharina Stering, Klaus Hergan, Brigitte Mlineritsch, Richard Greil
Figure S1. Cross table for calculation of sensitivity, specificity, PPV, NPV and accuracy. Figure S2. The negative predictive value (NPV) remained stable over time, while there were numerical differences in positive predictive value (PPV) at different time intervals; however, no trend towards improvement over time was evident. Figure S3. Residual pathologic tumor size (a) and residual cancer burden (RCB) score (b) in false positive rCR cases (rCR but no pCR = ypT0/is): 50 of 54 cases were analyzable. The mean size of residual disease in the pathologic specimen was 0.7 cm (range 0.1–5.0 cm). The median residual cancer burden score was 1.27 (range 0.66–3.86). Figure S4. Correlation between MRI and pathology report for determination of tumor size. Spearman test showed strong correlation between the two reports (Spearman Rho 0.57). Figure S5. C-indices demonstrating the performance of pCR, cCR and different clinicopathologic parameters for recurrence prediction. The values on the x-axis are estimates of the c-index of predicted probabilities in the corresponding binomial logistic regression models. P values indicate whether the ability of binomial logistic regression models to discriminate between patients with and without recurrence increases significantly by addition of more variables and they were computed by means of the Wilcoxon test. Stage: AJCC anatomic stage groups, 8th edition; HR: hormone receptor status. Figure S6. Kaplan-Meier curves for RFS according to pathologic (pCR) (a, c, e) and radiologic complete response (rCR) (b, d, f) after NACT for three different breast cancer subtypes: HR+/HER2- (a, b), triple-negative (c, d) and HER2+ (e, f). (PDF 331 kb)